Presented via GenomeWeb on May 27, 2020M2GEN’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. Through construction of comprehensive genotypic, transcriptomic, and phenotypic cohorts of consented cancer patients, M2GEN generates in silico avatars. M2GEN uses this information to accelerate cancer research, clinical trial matching, and development of real-world data comparator cohorts. The breadth and scope of the ORIEN Avatar clinical and molecular data enables the discovery of a wide array of DNA and RNA biomarkers, including those biomarkers associated with response to immuno-oncology agents.
As a partner in the ORIEN Avatar program, Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery, has conducted high-yield, high-quality dual RNA/DNA isolation from formalin-fixed, paraffin-embedded (FFPE) specimens as well as whole-exome sequencing and RNA sequencing services on more than 30,000 tumor and non-tumor samples. These genetic results, sharpened by ORIEN’s clinical data and the significant size of the sample set, accurately elucidate known drivers of cancer, identify new genetic alterations, and reveal novel potential therapeutic targets.
View this webinar to learn about:
- The utility of data from this large, high-quality sample set to guide immunotherapeutic development programs
- Large-scale sequencing of critical oncology biomarkers, including tumor mutational burden, microsatellite instability, small variants, splice variants, and fusions
- Optimized dual extraction methods from a single FFPE block that achieve highly accurate sequencing results across diverse tumor types and normal samples
- The cancer centers and partners driving M2GEN’s ORIEN Avatar program and how you can participate
- How you can access the ORIEN database to accelerate your oncology drug development studies
Check out the recording from this webinar here: